Intermediate monocytes and cytokine production associated with severe forms of chagas disease

Q1Monocytes are classified according to their CD14 and CD16 expression into classical (reparative), intermediate (inflammatory), and non-classical. This study assessed the frequency of monocyte and the relationship between monocyte subset percentages and the levels of blood cytokines in Colombian chagasic patients with different clinical forms. This study included chagasic patients in different clinical stages: indeterminate (IND) n = 14, chronic chagasic cardiomyopathy (CCC) n = 14, and heart transplant chagasic (HTCC) n = 9; controls with non-chagasic cardiopathy (NCC) n = 15, and healthy individuals (HI) n = 15. Peripheral blood mononuclear cells (PBMCs) were isolated, labeled for CD14, CD16, and HLA-DR, and analyzed by flow cytometry. Cytokines were measured with a bead-based immunoassay. Percentages of total CD14+ CD16+ and CD14+ HLA-DR+ monocytes were higher in patients with heart involvement (CCC, HTCC, and NCC) than controls. Percentages of intermediate monocytes increased in symptomatic chagasic patients (CCC and HTCC) compared to asymptomatic chagasic patients (IND) and controls (HI). Asymptomatic chagasic patients (IND) had higher percentages of classical monocytes, an increased production of CCL17 chemokine compared to chagasic symptomatic patients (CCC), and their levels of CCL17 was positively correlated with the percentage of classical monocyte subset. In CCC, the percentages of intermediate and classical monocytes were positively correlated with IL-6 levels, which were higher in this group compared to HI, and negatively with IL-12p40 concentration, respectively. Remarkably, there also was an important increased of classical monocytes frequency in three chronic chagasic patients who underwent cardiac transplant, of which one received anti-parasitic treatment. Our findings suggest that cardiac chagasic patients have an increased percentage of inflammatory monocytes and produce more IL-6, a biomarker of heart failure and left ventricular dysfunction, whereas asymptomatic chagasic individuals present a higher percentage of reparative monocytes and CCL17.N/

Anticitrullinated peptide antibodies (ACPA) in the serum of heavy smokers without arthritis - a differential role of associated pulmonary disease?

2 páginas, 1 tabla.-- Póster presentado al 5º European Workshop on Immune-Mediated Inflammatory Diseases celebrado en Sitges (Barcelona) del 1 al 3 de Diciembre de 2010.An increased risk of RA has been described in smokers, but only in ACPA-positive RA patients. The frequency of ACPA in serum of heavy smokers is not known.Peer reviewe

Use of the gluteus maximus muscle as the neosphincter for restoration of anal function after abdominoperineal resection

Q2Q1Artículo original425-429Background Our aim was to evaluate complications and long-term functional outcome in patients who had sphincter reconstruction using the gluteus maximus muscle as the neosphincter after abdominoperineal resection for rectal cancer treatment. Methods Seven patients underwent reconstruction from 2000 to 2010. First, the sigmoid colon was brought down to the perineum as a perineal colostomy, with the procedure protected by a loop ileostomy. Reconstruction of the sphincter mechanism using the gluteus maximus took place 3 months later, and after another 8–12 weeks, the loop ileostomy was closed. We studied the functional outcome of these interventions with follow-up interviews of patients and objectively assessed anorectal function using manometry and the Cleveland Clinic Florida (Jorge-Wexner) fecal incontinence score. Results The mean follow-up was 56 months (median 47; range 10–123 months). One patient had a perianal wound infection and another had fibrotic stricture in the colocutaneous anastomosis that required several digital dilatations. Anorectal manometry at 3-month follow-up showed resting pressures from 10 to 18 mm Hg and voluntary contraction pressures from 68 to 187 mm Hg. Four patients had excellent sphincter function (Jorge-Wexner scores ≤5). Conclusions Our preliminary results show that sphincter reconstruction by means of gluteus maximus transposition can be effective in restoring gastrointestinal continuity and recovering fecal continence in patients who have undergone APR with permanent colostomy for rectal cancer. Furthermore, the reconstruction procedure can be performed 2–4 years after the APR

Influence of Abiotic Factors Temperature and Water Content on Bacterial 2-Chlorophenol Biodegradation in Soils

Halogenated compounds are environmental pollutants toxic to humans and wildlife. Certain microorganisms degrade these halogenated compounds. However, little is known about the potential of microorganisms in bioremediation under extreme conditions, specifically in arid and semi-arid soils frequently exposed to high temperatures and desiccation periods. Arid and semi-arid environments and deserts make up vast areas of Earth's landmass. To investigate the degradation of 2-chlorophenol (2-CP) in soils as a function of temperature and water availability, three bacterial species were tested, two soil mesophiles of the genus Rhodococcus, R. opacus and R. erythropolis, and a soil thermophilic isolate, Parageobacillus thermoglucosidasius. Degradation trials in soil samples with these species were performed over a range of water activity from 1 to 0.4. At their optimum growth temperature, R. opacus showed maximum 2-CP degradation at water activity 0.9 sharply decreasing when lowering water activity. Nevertheless, the Parageobacillus isolate (optimum growth temperature 60°C) showed maximum 2-CP degradation rates at water activity 0.5 which represented highly desiccating conditions. Parageobacillus degradation of 2-CP was very low at water activity above 0.9. Thus, biodegradation of 2-CP in soils is possible even under arid conditions although different microbial species might be involved in this task depending on the interactions of abiotic factors and the diversity of microbial communities in soils. These results contribute to understand the potential biodegradation of specific halogenated compounds in the environment which is of great relevance to comprehend the fate of halogenated pollutants (i.e., 2-CP) in deserts, arid and semi-arid soils

Molecular characterization of TC964, a novel antigenic protein from trypanosoma cruzi

The Tc964 protein was initially identified by its presence in the interactome associated with the LYT1 mRNAs, which code for a virulence factor of Trypanosoma cruzi. Tc964 is annotated in the T. cruzi genome as a hypothetical protein. According to phylogenetic analysis, the protein is conserved in the different genera of the Trypanosomatidae family; however, recognizable orthologues were not identified in other groups of organisms. Therefore, as a first step, an in-depth molecular characterization of the Tc946 protein was carried out. Based on structural predictions and molecular dynamics studies, the Tc964 protein would belong to a particular class of GTPases. Subcellular fractionation analysis indicated that Tc964 is a nucleocytoplasmic protein. Additionally, the protein was expressed as a recombinant protein in order to analyze its antigenicity with sera from Chagas disease (CD) patients. Tc964 was found to be antigenic, and B-cell epitopes were mapped by the use of synthetic peptides. In parallel, the Leishmania major homologue (Lm964) was also expressed as recombinant protein and used for a preliminary evaluation of antigen cross-reactivity in CD patients. Interestingly, Tc964 was recognized by sera from Chronic CD (CCD) patients at different stages of disease severity, but no reactivity against this protein was observed when sera from Colombian patients with cutaneous leishmaniasis were analyzed. Therefore, Tc964 would be adequate for CD diagnosis in areas where both infections (CD and leishmaniasis) coexist, even though additional assays using larger collections of sera are needed in order to confirm its usefulness for differential serodiagnosisThis research was funded by Ministerio de Ciencia,Tecnología e Innovación (Minciencias) and Pontificia Universidad Javeriana, research project ID PPTA 120356933228 granted to C.J.P. The article publication was funded by the Vicerrectoría de Investigación from the Pontificia Universidad Javeriana, code 120813F0401200. The Network of Tropical Diseases Research RICET (RD16/0027/0008, Instituto de Salud Carlos III and co-funded by FEDER) to J.M.R., and grants from the Spanish Ministerio de Ciencia, Innovación y Universidades/Agencia Estatal de Investigación RTC-2017-6494-1 and RTI2018-094434-B-I00 (MCIU/AEI/FEDER, UE) to P.G.-P., E.R.-M and E.R.R. were supported by Minciencias convocatoria doctorados nacionales 647-2014 and convocatoria jóvenes investigadores e innovadores 706-2015, respectivel

Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis

Introduction: Evidence suggests that citrullinated fibrin(ogen) may be a potential in vivo target of anticitrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis (RA). We compared the diagnostic yield of three enzyme-linked immunosorbent assay (ELISA) tests by using chimeric fibrin/filaggrin citrullinated synthetic peptides (CFFCP1, CFFCP2, CFFCP3) with a commercial CCP2-based test in RA and analyzed their prognostic values in early RA. Methods: Samples from 307 blood donors and patients with RA (322), psoriatic arthritis (133), systemic lupus erythematosus (119), and hepatitis C infection (84) were assayed by using CFFCP- and CCP2-based tests. Autoantibodies also were analyzed at baseline and during a 2-year follow-up in 98 early RA patients to determine their prognostic value. Results: With cutoffs giving 98% specificity for RA versus blood donors, the sensitivity was 72.1% for CFFCP1, 78.0% for CFFCP2, 71.4% for CFFCP3, and 73.9% for CCP2, with positive predictive values greater than 97% in all cases. CFFCP sensitivity in RA increased to 80.4% without losing specificity when positivity was considered as any positive anti-CFFCP status. Specificity of the three CFFCP tests versus other rheumatic populations was high (> 90%) and similar to those for the CCP2. In early RA, CFFCP1 best identified patients with a poor radiographic outcome. Radiographic progression was faster in the small subgroup of CCP2-negative and CFFCP1-positive patients than in those negative for both autoantibodies. CFFCP antibodies decreased after 1 year, but without any correlation with changes in disease activity. Conclusions: CFFCP-based assays are highly sensitive and specific for RA. Early RA patients with anti-CFFCP1 antibodies, including CCP2-negative patients, show greater radiographic progression

Monte Carlo characterization of PETALO, a full-body liquid xenon-based PET detector

[EN] New detector approaches in Positron Emission Tomography imaging will play an important role in reducing costs, lowering administered radiation doses, and improving overall performance. PETALO employs liquid xenon as the active scintillating medium and UV-sensitive silicon photomultipliers for scintillation readout. The scintillation time in liquid xenon is fast enough to register time-of-flight information for each detected coincidence, and sufficient scintillation is produced with low enough fluctuations to obtain good energy resolution. The present simulation study examines a full-body-sized PETALO detector and evaluates its potential performance in PET image reconstruction.This work was supported by the European Research Council under grant ID 757829 and by Ministerio de Economia y Competitividad for grant FPA2016-78595-C3-1-R.Renner, J.; Romo-Luque, C.; Aliaga, RJ.; Álvarez-Puerta, V.; Ballester Merelo, FJ.; Benlloch-Rodríguez, J.; Carrión, J.... (2022). Monte Carlo characterization of PETALO, a full-body liquid xenon-based PET detector. Journal of Instrumentation. 17(5):1-14. https://doi.org/10.1088/1748-0221/17/05/P0504411417

Radiogenic backgrounds in the NEXT double beta decay experiment

[EN] Natural radioactivity represents one of the main backgrounds in the search for neutrinoless double beta decay. Within the NEXT physics program, the radioactivity- induced backgrounds are measured with the NEXT-White detector. Data from 37.9 days of low-background operations at the Laboratorio Subterraneo de Canfranc with xenon depleted in Xe-136 are analyzed to derive a total background rate of (0.84 +/- 0.02) mHz above 1000 keV. The comparison of data samples with and without the use of the radon abatement system demonstrates that the contribution of airborne-Rn is negligible. A radiogenic background model is built upon the extensive radiopurity screening campaign conducted by the NEXT collaboration. A spectral fit to this model yields the specific contributions of Co-60, K-40, Bi-214 and Tl-208 to the total background rate, as well as their location in the detector volumes. The results are used to evaluate the impact of the radiogenic backgrounds in the double beta decay analyses, after the application of topological cuts that reduce the total rate to (0.25 +/- 0.01) mHz. Based on the best-fit background model, the NEXT-White median sensitivity to the two-neutrino double beta decay is found to be 3.5 sigma after 1 year of data taking. The background measurement in a Q(beta beta)+/- 100 keV energy window validates the best-fit background model also for the neutrinoless double beta decay search with NEXT-100. Only one event is found, while the model expectation is (0.75 +/- 0.12) events.The NEXT collaboration acknowledges support from the following agencies and institutions: the European Research Council (ERC) under the Advanced Grant 339787-NEXT; the European Union's Framework Programme for Research and Innovation Horizon 2020 (2014-2020) under the Marie Sklodowska-Curie Grant Agreements No. 674896, 690575 and 740055; the Ministerio de Economia y Competitividad and the Ministerio de Ciencia, Innovacion y Universidades of Spain under grants FIS2014-53371-C04, RTI2018-095979, the Severo Ochoa Program SEV-2014-0398 and the Maria de Maetzu Program MDM-2016-0692; the GVA of Spain under grants PROMETEO/2016/120 and SEJI/2017/011; the Portuguese FCT under project PTDC/FIS-NUC/2525/2014, under project UID/FIS/04559/2013 to fund the activities of LIBPhys, and under grants PD/BD/105921/2014, SFRH/BPD/109180/2015 and SFRH/BPD/76842/2011; the U.S. Department of Energy under contracts number DE-AC02-06CH11357 (Argonne National Laboratory), DE-AC02-07CH11359 (Fermi National Accelerator Laboratory), DE-FG02-13ER42020 (Texas A&M) and DE-SC0019223/DE-SC0019054 (University of Texas at Arlington); and the University of Texas at Arlington. DGD acknowledges Ramon y Cajal program (Spain) under contract number RYC-2015-18820. We also warmly acknowledge the Laboratori Nazionali del Gran Sasso (LNGS) and the Dark Side collaboration for their help with TPB coating of various parts of the NEXT-White TPC. Finally, we are grateful to the Laboratorio Subterraneo de Canfranc for hosting and supporting the NEXT experiment.Novella, P.; Palmeiro, B.; Sorel, M.; Usón, A.; Ferrario, P.; Gómez-Cadenas, JJ.; Adams, C.... (2019). Radiogenic backgrounds in the NEXT double beta decay experiment. Journal of High Energy Physics (Online). (10):1-26. https://doi.org/10.1007/JHEP10(2019)051S12610KamLAND-Zen collaboration, Search for Majorana Neutrinos near the Inverted Mass Hierarchy Region with KamLAND-Zen, Phys. Rev. Lett.117 (2016) 082503 [arXiv:1605.02889] [INSPIRE].GERDA collaboration, Improved Limit on Neutrinoless Double-β Decay of76Ge from GERDA Phase II, Phys. Rev. Lett.120 (2018) 132503 [arXiv:1803.11100] [INSPIRE].NEXT collaboration, NEXT-100 Technical Design Report (TDR): Executive Summary, 2012JINST7 T06001 [arXiv:1202.0721] [INSPIRE].M. Redshaw, E. Wingfield, J. McDaniel and E.G. Myers, Mass and double-beta-decay Q value of Xe-136, Phys. Rev. Lett.98 (2007) 053003 [INSPIRE].EXO-200 collaboration, Improved measurement of the 2νββ half-life of136Xe with the EXO-200 detector, Phys. Rev.C 89 (2014) 015502 [arXiv:1306.6106] [INSPIRE].KamLAND-Zen collaboration, Measurement of the double-β decay half-life of136Xe with the KamLAND-Zen experiment, Phys. Rev.C 85 (2012) 045504 [arXiv:1201.4664] [INSPIRE].NEXT collaboration, Initial results on energy resolution of the NEXT-White detector, 2018JINST13 P10020 [arXiv:1808.01804] [INSPIRE].NEXT collaboration, Energy Calibration of the NEXT-White Detector with 1% Resolution Near Qββof136Xe, arXiv:1905.13110 [INSPIRE].NEXT collaboration, Near-Intrinsic Energy Resolution for 30 to 662 keV Gamma Rays in a High Pressure Xenon Electroluminescent TPC, Nucl. Instrum. Meth.A 708 (2013) 101 [arXiv:1211.4474] [INSPIRE].NEXT collaboration, Characterisation of NEXT-DEMO using xenon KαX-rays, 2014JINST9 P10007 [arXiv:1407.3966] [INSPIRE].NEXT collaboration, First proof of topological signature in the high pressure xenon gas TPC with electroluminescence amplification for the NEXT experiment, JHEP01 (2016) 104 [arXiv:1507.05902] [INSPIRE].NEXT collaboration, Demonstration of the event identification capabilities of the NEXT-White detector, arXiv:1905.13141 [INSPIRE].A.D. McDonald et al., Demonstration of Single Barium Ion Sensitivity for Neutrinoless Double Beta Decay using Single Molecule Fluorescence Imaging, Phys. Rev. Lett.120 (2018) 132504 [arXiv:1711.04782] [INSPIRE].P. Thapa et al., Barium Chemosensors with Dry-Phase Fluorescence for Neutrinoless Double Beta Decay, arXiv:1904.05901 [INSPIRE].NEXT collaboration, Ionization and scintillation response of high-pressure xenon gas to alpha particles, 2013 JINST8 P05025 [arXiv:1211.4508] [INSPIRE].NEXT collaboration, Initial results of NEXT-DEMO, a large-scale prototype of the NEXT-100 experiment, 2013 JINST8 P04002 [arXiv:1211.4838] [INSPIRE].NEXT collaboration, Operation and first results of the NEXT-DEMO prototype using a silicon photomultiplier tracking array, 2013 JINST8 P09011 [arXiv:1306.0471] [INSPIRE].NEXT collaboration, Description and commissioning of NEXT-MM prototype: first results from operation in a Xenon-Trimethylamine gas mixture, 2014 JINST9 P03010 [arXiv:1311.3242] [INSPIRE].NEXT collaboration, Ionization and scintillation of nuclear recoils in gaseous xenon, Nucl. Instrum. Meth.A 793 (2015) 62 [arXiv:1409.2853] [INSPIRE].NEXT collaboration, An improved measurement of electron-ion recombination in high-pressure xenon gas, 2015 JINST10 P03025 [arXiv:1412.3573] [INSPIRE].NEXT collaboration, Accurate γ and MeV-electron track reconstruction with an ultra-low diffusion Xenon/TMA TPC at 10 atm, Nucl. Instrum. Meth.A 804 (2015) 8 [arXiv:1504.03678] [INSPIRE].NEXT collaboration, The Next White (NEW) Detector, 2018 JINST13 P12010 [arXiv:1804.02409] [INSPIRE].NEXT collaboration, Sensitivity of NEXT-100 to Neutrinoless Double Beta Decay, JHEP05 (2016) 159 [arXiv:1511.09246] [INSPIRE].V. Alvarez et al., Radiopurity control in the NEXT-100 double beta decay experiment: procedures and initial measurements, 2013 JINST8 T01002 [arXiv:1211.3961] [INSPIRE].NEXT collaboration, Radiopurity assessment of the tracking readout for the NEXT double beta decay experiment, 2015 JINST10 P05006 [arXiv:1411.1433] [INSPIRE].NEXT collaboration, Radiopurity assessment of the energy readout for the NEXT double beta decay experiment, 2017 JINST12 T08003 [arXiv:1706.06012] [INSPIRE].NEXT collaboration, Measurement of radon-induced backgrounds in the NEXT double beta decay experiment, JHEP10 (2018) 112 [arXiv:1804.00471] [INSPIRE].NEXT collaboration, Electron drift properties in high pressure gaseous xenon, 2018 JINST13 P07013 [arXiv:1804.01680] [INSPIRE].NEXT collaboration, Calibration of the NEXT-White detector using83m Kr decays, 2018JINST13 P10014 [arXiv:1804.01780] [INSPIRE].NEXT collaboration, Background rejection in NEXT using deep neural networks, 2017JINST12 T01004 [arXiv:1609.06202] [INSPIRE].NEXT collaboration, Application and performance of an ML-EM algorithm in NEXT, 2017JINST12 P08009 [arXiv:1705.10270] [INSPIRE]

Experiencia colombiana en el tratamiento de la hepatitis C con agentes antivirales de acción directa

Experiencia colombiana en el tratamiento de la hepatitis C con agentes antivirales de acción directa. Existen pocas publicaciones de evidencias del mundo real sobre hepatitis C en América Latina. En este estudio presentamos una cohorte colombiana de pacientes tratados con agentes antivirales de acción directa. Fueron analizados retrospectivamente 195 pacientes seleccionados en 5 centros de hepatología en 4 ciudades de Colombia. Dos tercios fueron mujeres y la mitad tenía ≥ 62 años. De cada uno se cuantificaron biomarcadores séricos, escala de Child-Pugh, MELD y grado de cirrosis y fibrosis. Se cuantificó carga viral al inicio, al final y a las 12 semanas después de completado el tratamiento. Se comparó la frecuencia de efectos adversos de medicamentos en trasplantados vs. no trasplantados. Los pacientes recibieron 9 esquemas de tratamiento diferentes. El genotipo más prevalente fue 1b (81.5%). La respuesta viral sostenida fue alcanzada por 186 pacientes (95.4%). El grupo no trasplantado tenía mayor frecuencia de cirrosis (52.6% vs. 12.5%, p = 0.0004). En los trasplantados, la carga viral pre-tratamiento era mayor (1 743 575 IQR = 1 038 062-4 252 719 vs. 345 769 IQR = 125 806-842 239; p = < 0.0001) igual que la ALT y la AST (82.5 IQR 43.5-115.5 vs. 37.0 IQR = 24.7-73.3; p = 0.0009 and 70 IQR = 41-140 vs. 37 IQR = 24-68; p = 0.004 respectivamente). El 28.7% refirió efectos adversos, siendo el más prevalente la astenia (5.6%). Nuestros resultados fueron comparables a los de estudios publicados en términos de terapia y biomarcadores pero nuestra cohorte presentó menos efectos adversos. Se requiere más investigación en la región.Q4Q3Artículo original29-36There are few published real-world studies on hepatitis C in Latin America. This paper describes a cohort of Colombian subjects treated with direct-acting antiviral agents. A total of 195 patients from 5 hepatology centers in 4 Colombian cities were retrospectively studied. For each patient, serum biomarkers were obtained, and Child-Pugh, MELD, cirrhosis and fibrosis stage were calculated. Additionally, viral load was quantified at initiation, end of treatment and at 12 weeks of completion. Adverse effects were recorded. Patients with liver transplant were compared with non-transplanted patients in terms of serum biomarkers. The patients had received 9 different regimes. The most prevalent viral genotype was 1b (81.5%). Overall, 186 patients (95.4%) attained sustained virologic response. When comparing transplanted vs. non-transplanted patients, those in the non-transplanted group were more likely to have cirrhosis (52.6% vs. 12.5%, p = 0.0004). Pre-treatment viral load was higher in the transplant group (1 743 575 IQR = 1 038 062-4 252 719 vs. 345 769 IQR = 125 806-842 239; p < 0.0001) as well as ALT and AST levels (82.5 IQR 43.5-115.5 vs. 37.0 IQR = 24.7-73.3; p = 0.0009 and 70 IQR = 41-140 vs. 37 IQR = 24-68; p = 0.004 respectively). Adverse events were reported by 28.7% of the patients; asthenia (5.6%) was the most prevalent. Our results are comparable with those from other countries in terms of therapy and biomarkers. However, our cohort reported less adverse events. Further research is needed in the region

Digital inclusion and participation of people with intellectual disabilities during COVID-19: A rapid review and international bricolage

The COVID-19 pandemic has meant a rapid transfer of everyday activities to the online world. Information and communication technologies (ICTs) have become more embedded than ever in people's lives. This investigation addresses how this change has affected the lives of people with intellectual disabilities (ID). A two-step design was used. A rapid review was conducted on empirical studies published between January 2019 and June 2021. Search terms related to ID, ICT use and COVID-19. A qualitative international bricolage was also conducted corresponding to author nationalities. Data gathered from the review and bricolage were analysed separately using thematic analysis and relationally synthesised. Digital solutions to provide access to COVID-19 information and guidance seemed inadequate but were seldom empirically studied. Digital poverty, literacy and exclusion remain significant issues for people with ID internationally. People and their carers experienced reduced and removed service provision, loneliness and impoverished daily lives during the pandemic; amelioration of which was facilitated by digital solutions. One solution often used was videoconferencing. Prior experience of digital participation, adequate finances, connection, support and digital literacy mentoring for both people with ID and those providing services and support facilitated digital inclusion. Digital exclusion during COVID-19 was exacerbated by sociopolitical, structural, individual and support-related barriers. Although awareness of digital exclusion appears to have been raised, the extent to which this has led to action and change remains unclear. Despite digital exclusion and digital participation benefitting continuation of life, social and emotional well-being and autonomy, COVID-19 has not provided the impetus to eradicate digital poverty for people with ID. Governmental support, digital education, creativity and problem solving are required to enable people with ID the human right to be included in the digital world at this essential time and into the future